The reiteration of an Overweight rating and maintenance of a $45 price target by a reputable analyst like Louise Chen from Cantor Fitzgerald could instill confidence among investors and potentially lead to a positive short-term impact on Pfizer's stock price. The analyst's endorsement serves as a strong signal of the stock's value and future performance expectations.